CATTALYST: A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients (clinicaltrials.gov) - Oct 14, 2026 - P=N/A | N=3000 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2026 ➔ Jun 2028 | Trial primary completion date: Sep 2026 ➔ Jun 2028
Real-world evidence • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
|